Tatva-Chintan-Pharma-Chem-Ltd.-IPO-Elite-limited
  • By Elite Wealth
  • / July 16, 2021
  • / whatsnew
IPO-Note Tatva Chintan Pharma Chem Ltd
Rs-1073-Rs1083per Equity share Recommendation: Subscribe

Company Profile: –

Tatva Chintan Pharma Chem is a specialtychemical manufacturing company engaged in the production of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”). Company is the largest and only commercial manufacturer of SDAs for zeolites in India.SDAs are quarternary salts which are chemicals which helps in the formation of particular channels and pores during the synthesis of zeolites. Zeolites have varied applications including as catalysts and adsorbents.It serves customers across various industries, including the automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. It exports most of its products to over 25 countries, including the USA, China, Germany, Japan, South Africaand the UK

Open Your Demat Account to Invest in Upcoming IPO’s

open-demat-online

 

Tatva Chintan Pharma Chem Ltd IPO

Wants To Apply Online

Issue Details
bjects of the issue ·          Funding capital expenditure requirements for expansion of Dahej Manufacturing Facility

·          Funding capital expenditure requirements for upgradation at R&D facility in Vadodara

·          General corporate purposes

 

 

 

Issue Size Total issue Size -Rs. 500Cr.

Offer for Sale – Rs. 275 Cr.

Fresh Issue – Rs. 225 Cr

Face value  

Rs.10.00 Per Equity Share

Issue Price Rs. 1073 – Rs. 1083
Bid Lot 13shares
Listing at  

BSE, NSE

Issue Opens: 16thJuly, 2021 – 20th July, 2021
QIB 50% of Net Issue Offer
Retail 35% of Net Issue Offer
NIB 15% of Net Issue Offer

 

Check Tatva Chintan Pharma Chem Ltd IPO Allotment Status

Tatva Chintan Pharma Chem Ltd IPO allotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.

One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-

  1. To  Tatva Chintan Pharma Chem Ltd IPO Allotment Status
  2. Go to Application Status
  3. Select IPO as Tatva Chintan Pharma Chem Ltd
  4. Enter your PAN Number or Application Id or DP Client Id.

 

Tatva Chintan Pharma Chem Ltd IPO

Application Form

 

Elite-Empower-App-Promotional-Banner-img1

Financial Performance:

Financial -Performance-Tatva -Chintan-Pharma

Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoter Group 100.00% 79.17%
Public 20.83%
Source: RHP, EWL Research

Strengths:

  • Leading manufacturer of structure directing agents and phase transfer catalysts, with consistent quality.
  • Global presence with a wide customer base across various industries having high entry barriers
  • Diversified specialized product portfolio requiring strong technical know-how
  • Modern manufacturing facilities with a focus on ‘green’ chemistry processes

Key Highlights:

  • Revenue from operations has grown at a CAGR of 20.7% during FY19-FY21.
  • EBITDA Margin Increased from 21.4% in FY20 to 23.8% in FY21.
  • SDAs, PTC and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC) contributed40%, 27.1% and 30.4% respectively, in total revenue of company in FY21
  • Revenue from exports represent 70.58% of total revenue in FY21.
  • Current Ratio of the company stood at 1.56 in FY21.
  • Debt to Equity Ratio was 0.45 in FY21.
  • Raw material cost was 50.2% of the revenue of the company in FY21.

Risk Factors:

  • Increase in the cost of raw material could have adverse effect on financials.
  • Business risks in multiple countries could adversely affect the company
  • Continuing impact of the outbreak of the COVID-19 could have a significant effect on operations of the company

Outlook:

Tatva Chintan Pharma Chem is the only producer of SDAs in India and also enjoys the second largest position globally. Its key customers include Merck, Bayer AG, Asian Paints Ltd., Ipox Chemicals KFT, Laurus Labs Ltd., Tosoh Asia Pte. Ltd., SRF Limited, Navin Fluorine International Limited, Oriental Aromatics Ltd. etc. Global Specialty Chemicals Market values at $798 Billion in 2019 and is expected to grow at a CAGR of 5.3% from 2019-24.The existing customers of the company are largely pharmaceutical and agrochemical companies who are heavily dependent upon supplies from China. Post environmental issue that happened in China and China Plus One policy, countries have been looking for alternatives other than Chinese products. As the world recognizes more of green / clean energy and solutions, the use of SDA’s will increase and improve. At the higher end of the price band of Rs. 1083, the stock is offered at a PE multiple of45.9x on FY21 Post issue EPS of Rs. 23.58which is in line with industry.We would recommend Subscribe to this IPO considering future prospects of the company.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth
Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their
investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth
Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Manoj Vijay Shinde, Elite Wealth Limited, manojshinde@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their
securities. I/We also certify that no part of my compensation was, is or will be, directly or inirectly, related to the specific recommendations or views expressed in this
report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that
the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the
report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment
thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing
research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research.
For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure
documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available
to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of
coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth
Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company
in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. RavinderParkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course
Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and
Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research
report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of
the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public
appearance;
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company
in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage
services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research
report.
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided
by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of
clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or
brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.

Leave a Reply

Your email address will not be published. Required fields are marked *

FILING COMPLAINTS ON SCORES - EASY & QUICK

a. Register on SCORES portal

b. Mandatory details for filing complaints on SCORES:
i. Name, PAN, Address, Mobile Number, E-mail ID

c. Benefits:
i. Effective communication
ii. Speedy redressal of the grievances

SEBI : https://www.scores.gov.in/scores/complaintRegister.html